fenofibrate has been researched along with Cirrhosis in 20 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 7.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 7.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time." | 5.46 | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017) |
| " A rat model of renal transplantation was treated with the lipid-lowering drug, fenofibrate, and kidney fibrosis levels were determined by histochemical staining." | 4.31 | Targeted changes in blood lipids improves fibrosis in renal allografts. ( Li, G; Liu, B; Meng, Q; Wang, Y; Xu, ZX; Yang, H; Zhang, D; Zhang, YH; Zhou, H, 2023) |
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 3.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent." | 3.72 | Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 3.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| " We tested this hypothesis using rat thioacetamide (TAA) models of liver cirrhosis." | 3.72 | PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. ( Harano, Y; Itoh, Y; Kirishima, T; Minami, M; Morita, A; Nakamura, H; Okanoue, T; Toyama, T; Yamauchi, N, 2004) |
| "Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time." | 1.46 | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017) |
| "Fenofibrate was given to db/db mice in combination with anti-flt-1 hexamer and anti-flk-1 heptamer (VEGFR inhibition) for 12 weeks." | 1.40 | Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. ( Chang, YS; Cho, YR; Hong, BY; Kim, HW; Kim, MY; Kim, TW; Kim, YS; Lim, JH; Park, CW, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, Z | 1 |
| Zhao, Y | 1 |
| Tao, T | 1 |
| Guo, W | 1 |
| Liu, R | 1 |
| Huang, J | 1 |
| Xu, G | 1 |
| Horinouchi, Y | 1 |
| Murashima, Y | 1 |
| Yamada, Y | 1 |
| Yoshioka, S | 1 |
| Fukushima, K | 1 |
| Kure, T | 1 |
| Sasaki, N | 1 |
| Imanishi, M | 1 |
| Fujino, H | 1 |
| Tsuchiya, K | 1 |
| Shinomiya, K | 1 |
| Ikeda, Y | 1 |
| Zhang, YH | 1 |
| Liu, B | 1 |
| Meng, Q | 1 |
| Zhang, D | 1 |
| Yang, H | 1 |
| Li, G | 1 |
| Wang, Y | 4 |
| Zhou, H | 2 |
| Xu, ZX | 1 |
| Nakano, Y | 1 |
| Arima, T | 1 |
| Tobita, Y | 1 |
| Uchiyama, M | 1 |
| Shimizu, A | 1 |
| Takahashi, H | 1 |
| Cheng, L | 1 |
| Ge, M | 1 |
| Lan, Z | 1 |
| Ma, Z | 1 |
| Chi, W | 1 |
| Kuang, W | 1 |
| Sun, K | 1 |
| Zhao, X | 2 |
| Liu, Y | 1 |
| Feng, Y | 1 |
| Huang, Y | 1 |
| Luo, M | 1 |
| Li, L | 2 |
| Zhang, B | 1 |
| Hu, X | 1 |
| Xu, L | 1 |
| Liu, X | 1 |
| Huo, Y | 1 |
| Deng, H | 1 |
| Yang, J | 1 |
| Xi, Q | 1 |
| Zhang, Y | 2 |
| Siegenthaler, JA | 1 |
| Chen, L | 1 |
| Cevey, ÁC | 1 |
| Mirkin, GA | 1 |
| Donato, M | 1 |
| Rada, MJ | 1 |
| Penas, FN | 1 |
| Gelpi, RJ | 1 |
| Goren, NB | 1 |
| Kim, Y | 1 |
| Hwang, SD | 1 |
| Lim, JH | 2 |
| Kim, MY | 2 |
| Kim, EN | 1 |
| Choi, BS | 1 |
| Kim, YS | 2 |
| Kim, HW | 2 |
| Park, CW | 2 |
| Pang, L | 1 |
| Lin, J | 1 |
| Cho, YR | 1 |
| Kim, TW | 1 |
| Hong, BY | 1 |
| Chang, YS | 1 |
| Weng, H | 1 |
| Ji, X | 1 |
| Endo, K | 1 |
| Iwai, N | 1 |
| Zhang, J | 1 |
| Cheng, Y | 1 |
| Gu, J | 1 |
| Wang, S | 1 |
| Zhou, S | 1 |
| Tan, Y | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Mellen, N | 1 |
| Cheng, R | 2 |
| Ma, J | 1 |
| Zhang, C | 1 |
| Li, Z | 1 |
| Cai, L | 1 |
| Ding, L | 1 |
| He, X | 1 |
| Takahashi, Y | 1 |
| Ma, JX | 1 |
| Okada, M | 1 |
| Sano, F | 1 |
| Ikeda, I | 1 |
| Sugimoto, J | 1 |
| Takagi, S | 1 |
| Sakai, H | 1 |
| Yanai, T | 1 |
| Emmett, N | 1 |
| Mann, D | 1 |
| Iglarz, M | 1 |
| Touyz, RM | 1 |
| Viel, EC | 1 |
| Paradis, P | 1 |
| Amiri, F | 2 |
| Diep, QN | 2 |
| Schiffrin, EL | 2 |
| Benkirane, K | 1 |
| Cohn, JS | 1 |
| Endemann, D | 1 |
| Ogata, T | 1 |
| Miyauchi, T | 1 |
| Sakai, S | 1 |
| Takanashi, M | 1 |
| Irukayama-Tomobe, Y | 1 |
| Yamaguchi, I | 1 |
| Toyama, T | 1 |
| Nakamura, H | 1 |
| Harano, Y | 1 |
| Yamauchi, N | 1 |
| Morita, A | 1 |
| Kirishima, T | 1 |
| Minami, M | 1 |
| Itoh, Y | 1 |
| Okanoue, T | 1 |
| Duhaney, TA | 2 |
| Cui, L | 2 |
| Rude, MK | 1 |
| Lebrasseur, NK | 2 |
| Ngoy, S | 1 |
| De Silva, DS | 2 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Sam, F | 2 |
| Ip, PC | 1 |
| Joseph, L | 1 |
20 other studies available for fenofibrate and Cirrhosis
| Article | Year |
|---|---|
Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy.
Topics: Animals; Arrhythmogenic Right Ventricular Dysplasia; Biomarkers; Collagen Type I; Desmoglein 2; Dise | 2022 |
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Topics: Animals; Creatinine; Fenofibrate; Fibrosis; Kidney; Mice; PPAR alpha; Renal Insufficiency, Chronic; | 2023 |
Targeted changes in blood lipids improves fibrosis in renal allografts.
Topics: Allografts; Animals; Cholesterol; Fatty Acids, Omega-3; Fenofibrate; Fibrosis; Humans; Hyperlipidemi | 2023 |
Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
Topics: Animals; Burns, Chemical; Corneal Injuries; Corneal Neovascularization; Cytokines; Disease Models, A | 2020 |
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofib | 2018 |
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Diastole; Fenofibrate; Fibrosis; Humans; Inflammatio | 2017 |
Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line; Cell Proliferatio | 2019 |
Fenofibrate Improved Interstitial Fibrosis of Renal Allograft through Inhibited Epithelial-Mesenchymal Transition Induced by Oxidative Stress.
Topics: Animals; Cell Line; Epithelial Cells; Epithelial-Mesenchymal Transition; Fenofibrate; Fibrosis; Hydr | 2019 |
Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Blood | 2014 |
Pex11a deficiency is associated with a reduced abundance of functional peroxisomes and aggravated renal interstitial lesions.
Topics: Animals; Disease Models, Animal; Fatty Acids; Female; Fenofibrate; Fibrosis; Hypertension; Hypolipid | 2014 |
Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.
Topics: Animals; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2016 |
Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis.
Topics: Animals; beta Catenin; Blotting, Western; Cells, Cultured; Diabetic Nephropathies; Fenofibrate; Fibr | 2016 |
Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats.
Topics: Animals; Data Interpretation, Statistical; Fenofibrate; Fibrosis; Gene Expression; Gene Expression P | 2009 |
Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.
Topics: Actins; Animals; Collagen; Diabetic Nephropathies; Fenofibrate; Fibrosis; Hypolipidemic Agents; Infl | 2010 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En | 2003 |
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart | 2004 |
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
Topics: Animals; Blotting, Western; Cardiac Output, Low; Desoxycorticosterone; Diastole; Fenofibrate; Fibros | 2004 |
PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats.
Topics: Animals; Antioxidants; Blotting, Northern; Catalase; Densitometry; Fenofibrate; Fibrosis; Hydrogen P | 2004 |
Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Topics: Aldosterone; Animals; Cells, Cultured; Chronic Disease; Extracellular Signal-Regulated MAP Kinases; | 2007 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |